In the post-hoc analysis, researchers evaluated the time to onset of effect of galcanezumab as well as whether treatment with the study drug was associated with a reduction in migraine headache days.
Monthly subcutaneous injections of galcanezumab at either 120 mg or 300 mg were effective for preventing migraines.
Researchers have found that monthly subcutaneous injection of galcanezumab significantly reduce migraine headache days.
Monthly galcanezumab injections at 120 mg or 240 mg offer clinical benefit in reducing migraine pain.
Clinical Pain Advisor Articles
- Supervised Injection Sites: Facts, Information, Pros, and Cons
- Chronic Pain May Be a Contributing Factor to Suicide
- Striking a Balance Between Opioid Surveillance and Patient Privacy
- Demographic Characteristics of Pregnant Women With Opioid Use Disorder
- Effects of Mindfulness Therapy, Pharmacologic Prophylaxis on Catecholamine Levels in Migraine
- Perioperative Pain Management in Patients With Opioid Use Disorder
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- Antidepressant Effects of Ketamine Appear to Require Opioid System Activation
- Reviewing the Efficacy of Intrathecal Morphine, Ziconotide for Cancer- and Noncancer Chronic Pain
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Factors Associated With Suboptimal Interscalene Brachial Plexus Block for Arthroscopy
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- Scholarship Support Limited for Veterans Enrolling in MD Programs
- Alpha and Beta Band Activity in MS-Related Chronic Pain
- New Opioid-Induced Constipation Management Guidelines Available